Buy Like Buffett
Watchlist

Flagship explainer

How Indivior Pharmaceuticals, Inc. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$1.2B · 100%Cost of revenue$246M · 20%Gross profit$994M · 80%Operating income$262M · 21%Income before tax$239M · 19%Income tax$29M · 2%Net income$210M · 17%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$1.2B100%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-012237 · filed Feb 26, 2026
Cost of revenue$246M20%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-012237 · filed Feb 26, 2026
$994M80%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-012237 · filed Feb 26, 2026
$262M21%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-012237 · filed Feb 26, 2026
Income before tax$239M19%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-012237 · filed Feb 26, 2026
Income tax$29M2%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-012237 · filed Feb 26, 2026
$210M17%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-012237 · filed Feb 26, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-012237 · filed Feb 26, 2026
· event Dec 31, 2025 · retrieved Sep 4, 2026 · annual-row source set
Embed this chart

View the full Indivior Pharmaceuticals, Inc. analysis at Buy Like Buffett